RESUMEN
Background: anticardiolipin antibody [aCL] has been recognized as a marker for increased risk of Cerebral Vein Thrombosis [CVT]. However, there are only rare reports on CVT associated with other antibodies against different phospholipids such as phosphatidyl inositol, phosphatidyl serine, phosphatidic acid and beta 2 glycoprotein I. In this study, we studied the presence of these antiphospholipid antibodies [aPL], demographic and clinical characteristics in 30 patients with CVT
Methods: after diagnosis of CVT in 30 patients with MRI, we measured the titer of aCL and aPL [IgM and IgG] in all cases. The titers of IgG and IgM type of aPL and aCL were estimated in the sera
Results: anticardiolipin antibody was solely detected in 20% [n=6] and aCL and other aPL in 23.3% [ n=7] of patients, indicating one patient positive for other aPL but not for aCL [non-aCL]. Although the aPL positive group did not differ from the aPL-negative group from the stand point of clinical and demographic characteristics, yet seizure, infarct, superficial veins and sinus involvement and the use of OCP were seen more frequently in aPL-positive group
Conclusion: our findings suggest that in addition to aCL, other antiphospholipid antibodies may be an associated condition that plays a role in the pathogenesis of CVT. The presence of aPL in CVT patients is probably associated with more superficial sinus or veins involvement and as a result death rate was lower in aPL- positive group. Further investigations are necessary to establish this hypothesis